Solvonis Therapeutics Plc — MOU Reached with ICAD

Solvonis signs a non-binding MoU to assess adding Portugal to its Phase 3 AUD trial.

What the company is saying

Solvonis Therapeutics plc has signed a Memorandum of Understanding with ICAD, Portugal’s public addiction institute, and Panegreen to explore expanding its Phase 3 trial of SVN-001 for severe alcohol use disorder into Portugal. The company frames this as a strategic step to strengthen its European regulatory position by potentially adding EU patient data to the trial. The announcement emphasizes the involvement of national public health bodies in both the UK and Portugal, highlighting institutional credibility. CEO Anthony Tennyson and Independent Non-Executive Director Dr Renata Crome are quoted to reinforce the practical focus and the quality of the Portuguese partners. The company is clear that the MoU is non-binding, with a six-month term, and that any Portuguese trial participation remains subject to further approvals and funding agreements. The announcement also outlines Solvonis’s broader pipeline, including SVN-002 (planned US Phase 2b), SVN-114 (PTSD), and SVN-015 (stimulant use disorder and depression), but provides no new operational or financial metrics for these programs.

What the data suggests

The only realised fact is the signing of a non-binding MoU on 13 October 2026 to assess the feasibility of adding Portuguese sites to the ongoing 280-participant UK Phase 3 trial of SVN-001. The MoU’s initial term is six months and does not obligate any party to proceed. The assessment will cover operational aspects such as treatment capacity, recruitment, regulatory requirements, and costs, with a specific intention to determine if Portuguese site costs can match those of NHS sites in the UK. No data is provided on actual costs, funding commitments, or timelines for trial expansion. The company’s pipeline is described in qualitative terms, with no quantitative progress or financial updates for SVN-002, SVN-114, or SVN-015. The announcement is transparent about the current stage—an early framework for evaluation, not an execution milestone. There is no evidence of immediate financial impact or operational change.

Analysis

The announcement is positive in tone, highlighting the signing of a Memorandum of Understanding (MoU) to assess expanding a Phase 3 trial into Portugal. However, the MoU is explicitly non-binding and only initiates an assessment process, with all key operational and financial terms (costs, funding, regulatory approvals) still to be determined. Most claims are forward-looking, including the potential inclusion of Portuguese sites, future regulatory benefits, and pipeline progress, with only the MoU signing and ongoing UK trial as realised facts. The benefits of EU expansion and strengthened marketing authorisation are long-term and contingent on multiple approvals and agreements. The announcement references significant capital requirements (cost per participant, funding arrangements), but no actual funding or cost commitments are disclosed. The language inflates the signal by framing the MoU as a major milestone, when in reality it is an early-stage framework with no guarantee of execution.

Risk flags

• ●The MoU is non-binding and only initiates an assessment process, so there is no guarantee that Portuguese sites will be added to the Phase 3 trial. This introduces execution risk, as the project may not progress beyond the evaluation stage.
• ●Final costs and funding arrangements for the potential Portuguese expansion are not agreed and remain subject to negotiation. This creates financial uncertainty and could delay or prevent trial expansion if costs are higher than anticipated or funding cannot be secured.
• ●Regulatory, ethics, contractual, and governance approvals are all required before any Portuguese participation can proceed. Each of these steps introduces additional risk and potential for delay, especially when coordinating across multiple national agencies.
• ●The announcement inflates the significance of the MoU by framing it as a major milestone, but the actual operational impact is limited until binding commitments are secured. This gap between narrative and substance may mislead investors about the immediacy of value creation.

Bottom line

Solvonis’s announcement signals early-stage progress in its European expansion strategy for SVN-001, but the MoU with ICAD and Panegreen is non-binding and only covers an assessment phase. No operational, financial, or regulatory commitments have been made, and all key terms—costs, funding, and approvals—remain unresolved. The company’s narrative is credible in describing the process and partners but overstates the immediate impact by implying regulatory or commercial advantage before any expansion is agreed. Investors should treat this as a preliminary step, with no guarantee of trial expansion or near-term value. The most important takeaway is that tangible progress will depend on the outcome of the assessment, subsequent sponsor and funder decisions, and successful navigation of regulatory and financial hurdles.

Announcement summary

(LSE: SVNS) Solvonis Therapeutics plc has signed a Memorandum of Understanding (MoU) with ICAD, Portugal’s National Addiction Institute, and Panegreen – Health & Wellness Solutions, Lda. to assess the addition of Portuguese trial sites to the MORE-KARE UK Phase 3 trial of SVN-001 for severe alcohol use disorder (AUD). ICAD, attached to Portugal’s Ministry of Health, will help evaluate referral pathways and patient recruitment, while Panegreen, which operates The Clinic of Change in Lisbon, will coordinate the Portuguese work. The assessment will cover treatment capacity, start-up timelines, costs, potential investigators and trial sites, recruitment, treatment delivery, staffing and training, pharmacy and controlled-drug requirements, translation of trial materials, and Portuguese regulatory and ethics requirements. Solvonis will assess whether the cost per participant at Portuguese sites could be broadly in line with that charged by NHS sites in the UK. Final costs and funding arrangements remain subject to agreement. The MoU formalizes the European expansion plan announced on 25 August 2026, turning it into a signed framework with partners in Portugal in under two months. With ICAD on board, SVN-001’s Phase 3 programme now works with national public bodies in both the UK (NIHR and MRC) and Portugal. The planned inclusion of Portuguese patients in MORE-KARE would add EU clinical data to SVN-001’s Phase 3 evidence base, aiming to strengthen future marketing authorisation applications in selected EU countries or across the EU. The MoU has an initial six-month term and does not create a binding commitment to proceed with Portuguese trial participation; any participation remains subject to sponsor and funder agreement and the required ethics, regulatory, contractual, funding, and governance approvals. Solvonis will now take the proposal to the University of Exeter, NIHR, and MRC, with the assessment informing their consideration of Portuguese participation. SVN-001 combines ketamine with structured psychological therapy for severe AUD and is being evaluated in a 280-participant UK Phase 3 trial sponsored by the University of Exeter and co-funded by Solvonis, the National Institute for Health and Care Research (NIHR), and the Medical Research Council (MRC). Solvonis’ pipeline also includes SVN-002, advancing towards a planned Phase 2b trial in the United States for moderate-to-severe AUD, SVN-114 as a lead compound for PTSD, and SVN-015 for stimulant use disorder (StUD) and depression (MDD), with preclinical studies for StUD funded by the U.S. National Institute on Drug Abuse (NIDA). The company is also advancing proprietary CNS discovery programmes supported by a dedicated compound library and AI-enabled discovery capabilities.

Disagree with this article?